OTC Markets EXMKT - Delayed Quote USD
HAVN Life Sciences Inc. (HAVLF)
At close: November 6 at 3:00 PM EST
Breakdown
TTM
4/30/2022
4/30/2021
4/30/2020
Total Revenue
586.9760
276.4730
--
--
Cost of Revenue
378.3660
186.7800
--
--
Gross Profit
208.6100
89.6930
--
--
Operating Expense
4,533.8990
9,900.1590
24,345.6940
41.1240
Operating Income
-4,325.2890
-9,810.4660
-24,345.6940
-41.1240
Net Non Operating Interest Income Expense
14.7470
-34.1440
-17.4950
0.5480
Other Income Expense
-11,400.3740
-12,598.9380
-6,017.4440
--
Pretax Income
-15,710.9160
-22,443.5480
-30,380.6330
-40.5760
Net Income Common Stockholders
-15,710.9160
-22,443.5480
-30,380.6330
-40.5760
Diluted NI Available to Com Stockholders
-15,710.9160
-22,443.5480
-30,380.6330
-40.5760
Basic EPS
-3.11
-5.25
-15.51
-0.02
Diluted EPS
-3.11
-5.25
-15.51
-0.02
Basic Average Shares
7,129.3690
4,278.8170
1,958.9500
2,225.6990
Diluted Average Shares
7,129.3690
4,278.8170
1,958.9500
2,225.6990
Total Operating Income as Reported
-4,838.8760
-9,810.4660
-30,353.1380
--
Rent Expense Supplemental
58.6070
237.9340
121.2350
--
Total Expenses
4,912.2650
10,086.9390
24,345.6940
41.1240
Net Income from Continuing & Discontinued Operation
-15,710.9160
-22,443.5480
-30,380.6330
-40.5760
Normalized Income
-4,310.5420
-9,844.6100
-24,363.1890
-40.5760
Interest Income
--
30.0000
--
0.5480
Interest Expense
15.2530
64.1440
17.4950
--
Net Interest Income
14.7470
-34.1440
-17.4950
0.5480
EBIT
-15,695.6630
-22,379.4040
-30,363.1380
-40.5760
EBITDA
-15,508.1920
-21,803.7830
-25,758.6020
-40.5760
Reconciled Cost of Revenue
378.3660
186.7800
--
--
Reconciled Depreciation
187.4710
575.6210
4,604.5360
--
Net Income from Continuing Operation Net Minority Interest
-15,710.9160
-22,443.5480
-30,380.6330
-40.5760
Total Unusual Items Excluding Goodwill
-11,400.3740
-12,598.9380
-6,017.4440
--
Total Unusual Items
-11,400.3740
-12,598.9380
-6,017.4440
--
Normalized EBITDA
-4,107.8180
-9,204.8450
-19,741.1580
-40.5760
4/30/2020 - 10/20/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ONPPF Oncopeptides AB (publ)
0.2650
0.00%
ELVAF Evolva Holding SA
0.9500
0.00%
APTA.L Aptamer Group plc
0.2400
+4.35%
ANEB Anebulo Pharmaceuticals, Inc.
1.4701
-19.67%
CWBR CohBar, Inc.
0.5105
+3.13%
KRBP Kiromic BioPharma, Inc.
0.9150
-20.43%
ARDS Aridis Pharmaceuticals, Inc.
0.0002
0.00%
ATXS Astria Therapeutics, Inc.
11.77
-0.84%
SABS SAB Biotherapeutics, Inc.
3.2700
-17.22%
ALVR AlloVir, Inc.
0.9815
-2.82%